PARP1 and cancer: In conclusion, by thoroughly elucidating the molecular mechanism of IP-DNQ against NQO1-positive cancers, our study offers the first translational evidence supporting the exploration of combination therapy with IP-DNQ and ionizing radiation (IR) or other antitumor drugs (e.g., PARP1 inhibitors and PCNA inhibitors).